Efficacy Differences Within Drug Classes Unsupported By Data, FDA's Temple Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Studies that look for differences in efficacy among members of the same drug class are only performed when necessary for approval, CDER Office of Medical Policy Director Temple tells DIA. While questioning the introduction of "follow-on" compounds, Temple also highlights AstraZeneca's success in achieving a more optimal dose for Nexium.
You may also be interested in...
Follow-On Brand Drugs Could Draw FTC Anticompetitive Scrutiny
Introduction of certain types of successor drugs as the original product nears patent expiration has "caught the attention" of individuals at FTC, Commissioner Harbour tells BIO annual conference. A company's history and methods of engaging in this practice to blunt generic competition could open it up to agency scrutiny, she says.
Bextra Pulled From Market, But Pfizer Hopes To Explore Other Options
Pfizer is characterizing FDA's request for a withdrawal of Bextra as a "marketing suspension"; the company hopes to continue discussions on how valdecoxib could re-enter the market. Increased cardiovascular risk plus a "special risk" of serious skin reactions led FDA to recommend pulling the COX-2 inhibitor.
COX-2 Cardio Risk Is Class Effect, But Varies By Drug And Dose, Cmte. Says
While a COX-2 class signal is likely, several committee members suggest data are not conclusive enough to make a "global" statement on the class. Voting FDA consultant Nissen recommends FDA explore whether COX-2 inhibition plays a role in hypertension, thereby contributing to an increased cardiovascular risk.